| Patient | Higuchi Ichiyō |
|---|---|
| Date of birth | 1872-05-02 |
| Identifiers | MRN HR-NI029-SYN-TD; SSN (made up) 000-29-5108 |
| Document date | 1896-08-24 |
| Author | Aiko Lindgren-Tanaka, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Ms. Higuchi is a 24-year-old writer with drug-susceptible pulmonary tuberculosis in the nineteenth week of treatment, now in the continuation phase on isoniazid, rifampin and pyridoxine by video-observed therapy, who comes for the preventive visit booked at her first appointment. Her cough and night sweats have gone, she sleeps well, and she has gained 4 kg since intake. The cystitis five weeks ago settled within two days on nitrofurantoin, and the culture grew Escherichia coli susceptible to it. The sputum culture taken at the end of the intensive phase showed no growth after six weeks. She writes about two hours each morning and has finished a new story. Public funding now covers most of her tuberculosis costs, and the social worker helped her arrange to pay her clinic charges in instalments. She has no new concerns. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 24 |
| Tuberculosis | Week 19 of 26; no symptoms; every dose taken |
| Cystitis | Resolved |
| Mood | PHQ-2 1; GAD-7 4 |
Health risk assessment. Completed by the patient on paper in the waiting room and reviewed with her by Dr. Lindgren-Tanaka. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good and improving |
| Psychosocial | Money is her main stress; less worried now that treatment costs are covered; feels supported by her editors and readers |
| Substance use | AUDIT-C 0; no drug use |
| Tobacco | Never smoked; no one smokes at home |
| Physical activity | Walks to the market and back most days, about 30 minutes |
| Nutrition | Three meals and two snacks a day with two supplement drinks; more fish, eggs and tofu since the dietitian visits |
| Sleep | Seven hours; writing moved from night to morning |
| Safety | Feels safe at home; intimate partner violence screen negative; smoke alarm at home |
| Sexual and reproductive health | Not sexually active; not planning a pregnancy; regular periods |
| Activities of daily living | Independent |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats or weight loss; weight rising |
| Eyes | Negative | No change in vision or color vision |
| Ears, nose, mouth, and throat | Negative | No sore throat or hearing change |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough, sputum or breathlessness |
| Gastrointestinal | Negative | No nausea, abdominal pain or jaundice |
| Genitourinary | Negative | No urinary symptoms since the cystitis; urine orange from rifampin |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No rash |
| Neurological | Negative | No numbness or tingling in the hands or feet |
| Psychiatric | Negative | Mood good; PHQ-2 1 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 100 mg tablets, two tablets (200 mg) daily | 200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily | 450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phase | Oral route | 1896-04-17 to 1896-06-11 | completed | S |
| Ethambutol 100 mg tablets, six tablets (600 mg) daily | 600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results return | Oral route | 1896-04-17 to 1896-05-22 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Nitrofurantoin monohydrate/macrocrystals 100 mg oral capsule, one capsule twice daily with food for five days | One capsule twice daily with food for five days | Oral route | 1896-07-20 to 1896-07-24 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1896-08-24 | Body height | 148 | cm | S |
| 1896-08-24 | Body weight | 42.6 | kg | S |
| 1896-08-24 | Body mass index (BMI) [Ratio] | 19.4 | kg/m2 | S |
| 1896-08-24 | Systolic blood pressure | 104 | mm[Hg] | S |
| 1896-08-24 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1896-08-24 | Heart rate | 76 | /min | S |
| 1896-08-24 | Respiratory rate | 14 | /min | S |
| 1896-08-24 | Body temperature | 36.6 | Cel | S |
| 1896-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1896-08-24 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1896-08-24 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | {score} | S | ||
| 1896-08-24 | Total score [AUDIT-C] | 0 | {score} | S |
Vital signs recorded on 1896-08-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Slim and well; weight 42.6 kg, BMI 19.4; blood pressure 104/66 |
| Eyes | No icterus; conjunctivae pink |
| Neck | No enlarged lymph nodes; thyroid normal |
| Respiratory | Clear on both sides |
| Cardiovascular | Regular rhythm; no murmur |
| Abdomen | Soft and non-tender; liver not enlarged |
| Genitourinary | Speculum examination with a small speculum, with a chaperone and her consent: normal cervix; cytology sample taken |
| Neurological | Normal sensation and reflexes in the feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and culture | resolved | confirmed | R05.3 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D). |
| Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected) | active | confirmed | A15.0 | S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic. |
| Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dL | active | confirmed | E44.0 | S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty. |
| Low and irregular income from writing, with a household to support; costs of care are a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented poverty and household responsibilities. |
| Acute uncomplicated cystitis, treated with nitrofurantoin rather than a fluoroquinolone during tuberculosis treatment; resolved | resolved | confirmed | N30.00 | S — Synthetic intercurrent illness; not a historical claim. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 104/66 mmHg |
| Depression screening | Completed today | PHQ-2 score 1 |
| Anxiety screening | Completed today | GAD-7 score 4 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 0 |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Asked privately; negative |
| Cervical cancer screening | Completed today | Cytology at 24, her first screening; every three years from 21 to 29 |
| Chlamydia and gonorrhea screening | Not indicated | Not sexually active; offer when that changes, as for sexually active women 24 or younger |
| Contraception and pregnancy intention | Completed today | Not planning a pregnancy; counseled on the rifampin interaction with hormonal methods |
| Folic acid | Completed today | Advised 0.4 to 0.8 mg daily, as for anyone who could become pregnant |
| HIV screening | Up to date | Negative at intake |
| Hepatitis C screening | Up to date | Negative at intake |
| Hepatitis B screening | Up to date | At intake: surface antigen, surface antibody and core antibody negative; not immune |
| Diabetes screening | Up to date | Hemoglobin A1c 5.1% at intake, checked because diabetes worsens tuberculosis outcomes |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap; no adult booster recorded |
| Hepatitis B vaccine | Completed today | Dose 1 of 2 today; dose 2 in eight weeks |
| HPV vaccine | Completed today | Catch-up dose 1 of 3 today, through age 26 |
| Influenza vaccine | Due | In the autumn, at the end-of-treatment visit |
| COVID-19 vaccine | Due | Discuss in the autumn |
Immunizations given today: Tetanus, diphtheria, and acellular pertussis vaccine (Tdap); Hepatitis B vaccine (HepB-CpG), dose 1 of 2; Human papillomavirus 9-valent vaccine, dose 1 of 3 [S]
Guideline basis: Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Cervical Cancer: Screening (2018); U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024); Adult Immunization Schedule by Age (2026)
Follow-up: End-of-treatment visit after the 182nd dose, with the chest X-ray, blood tests, the second hepatitis B and HPV doses and the influenza vaccine. Cytology result by phone. Next preventive visit in one year. Next scheduled visit 1896-10-20: end-of-treatment review after 182 doses. [S]
Voluntary advance care planning discussion of about 16 minutes, with her consent. She understands that her tuberculosis is curable and wants full treatment of any illness. She named a health care agent, recorded in the confidential part of the chart and not named here, and chose to record no other preferences today. To be revisited yearly. [S]